Moderna, Inc. Common Stock vs. REGENXBIO Inc.
Moderna, Inc. Common Stock and REGENXBIO Inc. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| MRNA | RGNX | |
|---|---|---|
| Market Cap | $55.45 billion | $531.74 million |
| Revenue (TTM) | $2.23 billion | $174.48 million |
| Net Income (TTM) | $-3,151,000,000 | $-196,432,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| MRNA | RGNX | |
|---|---|---|
| Price / Book | 8.20 | 7.41 |
| Price / Sales | 24.89 | 3.05 |
RGNX leads on 2 of 2 valuation factors.
Profitability
| MRNA | RGNX | |
|---|---|---|
| Net Margin | -141.43% | -112.58% |
| Return on Equity | -46.61% | -273.72% |
MRNA and RGNX split the profitability factors evenly.
Risk & Sentiment
| MRNA | RGNX | |
|---|---|---|
| Short Interest | 0.01% | 1.96% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: MRNA overview, MRNA financials, RGNX overview, RGNX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.